JP2015522561A5 - - Google Patents

Download PDF

Info

Publication number
JP2015522561A5
JP2015522561A5 JP2015516198A JP2015516198A JP2015522561A5 JP 2015522561 A5 JP2015522561 A5 JP 2015522561A5 JP 2015516198 A JP2015516198 A JP 2015516198A JP 2015516198 A JP2015516198 A JP 2015516198A JP 2015522561 A5 JP2015522561 A5 JP 2015522561A5
Authority
JP
Japan
Prior art keywords
galacto
composition
kda
rhamnogalacturonate
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015516198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522561A (ja
JP6517141B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/044478 external-priority patent/WO2013184892A1/en
Publication of JP2015522561A publication Critical patent/JP2015522561A/ja
Publication of JP2015522561A5 publication Critical patent/JP2015522561A5/ja
Application granted granted Critical
Publication of JP6517141B2 publication Critical patent/JP6517141B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015516198A 2012-06-06 2013-06-06 高誘導型一酸化窒素合成酵素と関連する疾患を処置するためのガラクト−ラムノガラクツロネート組成物 Active JP6517141B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261656288P 2012-06-06 2012-06-06
US61/656,288 2012-06-06
PCT/US2013/044478 WO2013184892A1 (en) 2012-06-06 2013-06-06 Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase

Publications (3)

Publication Number Publication Date
JP2015522561A JP2015522561A (ja) 2015-08-06
JP2015522561A5 true JP2015522561A5 (cg-RX-API-DMAC7.html) 2016-07-14
JP6517141B2 JP6517141B2 (ja) 2019-05-22

Family

ID=49712624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015516198A Active JP6517141B2 (ja) 2012-06-06 2013-06-06 高誘導型一酸化窒素合成酵素と関連する疾患を処置するためのガラクト−ラムノガラクツロネート組成物

Country Status (13)

Country Link
US (1) US9763974B2 (cg-RX-API-DMAC7.html)
EP (1) EP2858651B1 (cg-RX-API-DMAC7.html)
JP (1) JP6517141B2 (cg-RX-API-DMAC7.html)
KR (1) KR102071739B1 (cg-RX-API-DMAC7.html)
CN (1) CN104619329B (cg-RX-API-DMAC7.html)
AU (1) AU2013271585B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014030534A2 (cg-RX-API-DMAC7.html)
CA (1) CA2875979C (cg-RX-API-DMAC7.html)
ES (1) ES2848538T3 (cg-RX-API-DMAC7.html)
IL (1) IL236067B (cg-RX-API-DMAC7.html)
MX (1) MX2014014979A (cg-RX-API-DMAC7.html)
WO (1) WO2013184892A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201409195B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
CN104245717B (zh) 2011-12-28 2017-10-24 卡莱克汀医疗有限公司 用于治疗人类疾病的新型糖类药物的组合物
WO2013184892A1 (en) 2012-06-06 2013-12-12 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
JP6415437B2 (ja) 2012-09-17 2018-10-31 ガレクティン・セラピューティクス・インコーポレイテッドGalectin Therapeutics, Inc. 癌の処置における特異的免疫療法を向上する方法
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
JP2017525702A (ja) * 2014-08-18 2017-09-07 ファーマジェネシス, インコーポレイテッド ポリガラクツロナンラムノガラクツロナン(pgrg1)組成物
CA3102155A1 (en) 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugates
WO2021064729A1 (en) * 2019-10-02 2021-04-08 Patchor Ltd. Injectable composition for the treatment of musculoskeletal disorders and methods of use thereof
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897A (en) 1851-01-14 Improvement in raising carriage-tops
US583A (en) 1838-01-27 Hviprovement in horizontal windmills
US2132577A (en) 1934-08-28 1938-10-11 Gen Foods Corp Method of preparing pectin
US2444266A (en) 1944-03-31 1948-06-29 Us Agriculture Pectic materials and method of preparing same
US2503258A (en) 1948-01-23 1950-04-11 Us Agriculture Neutralization of pectinic acids with sodium bicarbonate
US4016351A (en) 1976-02-04 1977-04-05 Eschinasi Emile H Pectic substances with varying methoxyl content and process therefor
US4268533A (en) 1979-11-21 1981-05-19 General Foods Corporation Quick-set low methoxyl pectin composition
JPS61502124A (ja) 1984-05-09 1986-09-25 ジ オ−ストラリアン ナシヨナル ユニヴア−シテイ− 免疫応答の調節方法
US4686106A (en) 1986-06-16 1987-08-11 General Foods Corporation Pectin food product
US5071970A (en) 1988-11-23 1991-12-10 University Of Florida Process for producing pectin with a high-to-medium methoxyl content from beet pulp
DE4011285A1 (de) 1990-04-06 1991-10-10 Steigerwald Arzneimittelwerk Arzneimittel zur behandlung von hyperlipidaemie und/oder atherosklerose
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US7491708B1 (en) 1993-03-01 2009-02-17 David Platt Modified pectin
US5498702A (en) 1993-12-16 1996-03-12 California Natural Products Treated pectinic acid process and product
US5834442A (en) 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US6297229B1 (en) 1994-11-14 2001-10-02 Mayo Foundation For Medical Education And Research Use of ursodeoxycholic acid to treat nonalcoholic steatohepatitis
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5681923A (en) 1995-10-06 1997-10-28 Platt; David Tumor derived carbohydrate binding protein
US6632797B2 (en) 1996-06-24 2003-10-14 Matti Siren Method of treating angiogenesis
JPH10117800A (ja) * 1996-08-30 1998-05-12 Akita Pref Gov 単糖、オリゴ糖または可溶化多糖の製造法
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US5929051A (en) * 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins
US6180139B1 (en) 1998-12-04 2001-01-30 Viva America Marketing, Inc. Composition and method for treating nonalcoholic steatohepatitis
US6500807B1 (en) 1999-02-02 2002-12-31 Safescience, Inc. Modified pectin and nucleic acid composition
AU4055000A (en) 1999-04-13 2000-11-14 Daniel K. Hsu Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
US6592910B1 (en) 1999-04-20 2003-07-15 Board Of Trustees, Southern Illinois University Methods of treating clinical diseases with isoflavones
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
CN1142272C (zh) 2000-02-02 2004-03-17 中国人民解放军军事医学科学院百环生物医学研究中心 携带人肝细胞生长因子基因的重组腺病毒的用途
CN100558407C (zh) 2000-02-04 2009-11-11 柳署弘 制备含有胆汁酸的澄清水溶液剂型
US6596762B2 (en) 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
US6770622B2 (en) 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20030004132A1 (en) 2001-06-22 2003-01-02 Yan Chang Method and material for treating immune diseases
CN1549724A (zh) 2001-07-20 2004-11-24 ����ͨѶ�ɷ����޹�˾ 治疗肝纤维化的方法
US6890906B2 (en) 2001-11-21 2005-05-10 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US20040121981A1 (en) 2001-11-21 2004-06-24 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US7312208B2 (en) 2002-08-28 2007-12-25 Asahi Kasei Pharma Corporation Quaternary ammonium compounds
JP2004107295A (ja) 2002-09-20 2004-04-08 National Agriculture & Bio-Oriented Research Organization ヒスタミン遊離抑制剤
EP1980257A1 (en) 2003-04-07 2008-10-15 Prospect Therapeutics, Inc. Compositions and uses of galectin antagonists
US20040223971A1 (en) 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
WO2004096998A2 (en) 2003-04-29 2004-11-11 Vanderbilt University Nanoparticular tumor targeting and therapy
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US7078064B2 (en) 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
AU2005217318B2 (en) 2004-02-27 2010-07-01 Asahi Kasei Pharma Corporation Novel benzothiazepine and benzothiepine compounds
EP1765874A1 (en) 2004-03-26 2007-03-28 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
JP2008105945A (ja) 2005-02-07 2008-05-08 Ajinomoto Co Inc アディポネクチンの分泌促進又は誘導作用を有するアシルアミド化合物
EP1924294A4 (en) 2005-05-24 2010-11-03 Isis Pharmaceuticals Inc COMPOSITIONS AND ITS USES AGAINST PTPRU
RU2007148927A (ru) 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
DE602006010870D1 (de) 2005-06-20 2010-01-14 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
US7897591B2 (en) 2005-07-28 2011-03-01 Children's Medical Center Corporation Method of treating fatty liver disease
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
JP5105297B2 (ja) 2006-05-25 2012-12-26 味の素株式会社 Ppar活性調節剤
US7754745B2 (en) 2006-06-13 2010-07-13 Merck Frosst Canada Ltd. Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
WO2009070781A1 (en) 2007-11-30 2009-06-04 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
WO2009118343A1 (en) 2008-03-27 2009-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for determining the occurrence of a liver disease in a subject
KR101074158B1 (ko) 2008-04-07 2011-10-17 재단법인 한국원자력의학원 간 보호 또는 간 질환의 예방 및 치료용 인삼다당체 조성물
US20110082119A1 (en) 2008-06-13 2011-04-07 Takashi Yano Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
JP2010229099A (ja) 2009-03-27 2010-10-14 Mochida Pharmaceut Co Ltd 脂質異常症の改善または治療薬
EP2732053B1 (en) 2011-07-14 2017-10-25 Progenity, Inc. Systems, apparatus and methods for biochemical analysis
CA2848711C (en) * 2011-09-16 2019-08-06 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
CN104245717B (zh) * 2011-12-28 2017-10-24 卡莱克汀医疗有限公司 用于治疗人类疾病的新型糖类药物的组合物
WO2013184892A1 (en) 2012-06-06 2013-12-12 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
JP6415437B2 (ja) 2012-09-17 2018-10-31 ガレクティン・セラピューティクス・インコーポレイテッドGalectin Therapeutics, Inc. 癌の処置における特異的免疫療法を向上する方法

Similar Documents

Publication Publication Date Title
JP2014526513A5 (cg-RX-API-DMAC7.html)
ES2848538T3 (es) Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible
EP2178565A1 (fr) COMPLEXES ENTRE UN POLYMÈRE AMPHIPHILE ET UNE PROTÉINE OSTÉOGÉNIQUE APPARTENANT À LA FAMILLE DES BMPs
ES2985807T3 (es) Compuestos de tolano para favorecer la cicatrización de heridas
HRP20210034T1 (hr) Farmaceutski pripravci koji sadrže meloksikam i rizatriptan
FR2891149A1 (fr) Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
JP2015503658A5 (cg-RX-API-DMAC7.html)
WO2011015634A3 (en) Controlled release formulations of lipocalin muteins
BR112017027985A2 (pt) peptídeos terapêuticos e métodos de uso dos mesmos
CN111050778B (zh) 具有化学修饰的骨架的生物缀合物
US20250009664A1 (en) Dosage form for intra-articular injection comprising colchicine for use in the treatment of crystal-and non-crystal associated acute inflammatory arthritis
JP2016512247A5 (cg-RX-API-DMAC7.html)
KR20250134143A (ko) 골관절염과 같은 관절 질환의 치료에서 사용하기 위한 콜키신을 포함하는 관절내 주사용 제형
Jin et al. Prolonged plasma exposure of the Kv1. 3-inhibitory peptide HsTX1 [R14A] by subcutaneous administration of a poly (lactic-co-glycolic acid)(PLGA) microsphere formulation
CA3028042A1 (en) Compositions comprising a polysaccharide matrix for the controlled release of active ingredients
AU2023370236A1 (en) Dosage form for intra-articular injection comprising colchicine and an anesthesic agent in the treatment of crystal-and non-crystal associated acute inflammatory arthritis
Singh et al. CD44 as the target site for hyaluronic acid in favor of colitis management
Gumus et al. mTOR pathway and its role in rheumatologic diseases/mTOR yolagi ve romatolojik hastaliklardaki rolu.
WO2015014730A4 (en) Polysaccharide for use in preventing metastasis formation and/or relapse
CO2021009028A2 (es) Composiciones para uñas con propiedades antifúngicas
CN111491640A (zh) 包含葡聚糖或泊咯沙姆的用于治疗关节疾病或结缔组织病的组合物
Abdalla et al. Supplement with Cystoseira canariensis promotes an increase of resistance to the maximum load in the grastrocnemius muscle of female rats
Siddique et al. Incidence of Periprocedural Myocardial Infarction and use of Statin